title: Effect of board certification on antihypertensive treatment intensification in patients with diabetes mellitus.
abstract: BACKGROUND
  Regular recertification is mandatory to maintain board certification status in all specialties. However, the evidence that physicians' performance decreases with time since initial certification is limited. We therefore carried out a study to determine whether the frequency of antihypertensive treatment intensification for diabetic patients changes with time since their physicians' last board certification.
  
  
  RESULTS
  In this retrospective cohort study, we analyzed treatment of 8127 hypertensive patients with diabetes mellitus treated by 301 internists at primary care practices affiliated with 2 large academic hospitals. Patient visits with documented blood pressure > or = 130/85 mm Hg between January 1, 2000, and August 31, 2005, were studied. The association between the number of years since the physician's last board certification and the probability of pharmacological antihypertensive treatment intensification at a given visit was analyzed. Frequency of treatment intensification decreased from 26.7% for physicians who were board certified the previous year to 6.9% for physicians who were board certified 31 years before the visit. Treatment intensification rate was 22.5% for physicians certified < or = 10 years ago versus 16.9% for physicians last certified > 10 years ago (P<0.0001). Multivariable analysis adjusted for patient and visit characteristics and physician age showed that for every decade since the physician's last board certification, the probability of treatment intensification decreased by 21.3% (P=0.0097).
  
  
  CONCLUSIONS
  Physician intensification of pharmacological therapy for blood pressure levels above the recommended treatment goals decreases with time since the last board certification. This finding supports the current policy of mandatory recertification.
authors.affiliation: Division of Endocrinology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115, USA. aturchin@partners.org
authors.forename: Alexander
authors.initials: A
authors.lastname: Turchin
authors.forename: Maria
authors.initials: M
authors.lastname: Shubina
authors.forename: Anna H
authors.initials: AH
authors.lastname: Chodos
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Einbinder
authors.forename: Merri L
authors.initials: ML
authors.lastname: Pendergrass
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D002568:Certification / Q000331:legislation & jurisprudence*; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000517:prevention & control*; D010820:Physicians; D012189:Retrospective Studies; D014481:United States
chemical_list: D000959:Antihypertensive Agents